ATE250427T1 - Zusammensetzungen und deren verwendung zur hemmung von angiogenese - Google Patents
Zusammensetzungen und deren verwendung zur hemmung von angiogeneseInfo
- Publication number
- ATE250427T1 ATE250427T1 AT99954789T AT99954789T ATE250427T1 AT E250427 T1 ATE250427 T1 AT E250427T1 AT 99954789 T AT99954789 T AT 99954789T AT 99954789 T AT99954789 T AT 99954789T AT E250427 T1 ATE250427 T1 AT E250427T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- angiogenesis
- compositions
- inhibiting angiogenesis
- cell proliferation
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10352698P | 1998-10-08 | 1998-10-08 | |
US11613199P | 1999-01-15 | 1999-01-15 | |
PCT/US1999/023450 WO2000020026A2 (en) | 1998-10-08 | 1999-10-08 | Compositions and methods for inhibiting angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE250427T1 true ATE250427T1 (de) | 2003-10-15 |
Family
ID=26800564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99954789T ATE250427T1 (de) | 1998-10-08 | 1999-10-08 | Zusammensetzungen und deren verwendung zur hemmung von angiogenese |
Country Status (8)
Country | Link |
---|---|
US (2) | US6607724B2 (de) |
EP (1) | EP1117428B1 (de) |
JP (1) | JP2002526418A (de) |
AT (1) | ATE250427T1 (de) |
AU (1) | AU768076B2 (de) |
CA (1) | CA2344613A1 (de) |
DE (1) | DE69911629D1 (de) |
WO (1) | WO2000020026A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358735B1 (en) | 1995-06-30 | 2002-03-19 | University Of Kansas Medical Center | Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen |
US6440729B1 (en) | 1995-06-30 | 2002-08-27 | University Of Kansas Medical Center | Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen |
CA2368608A1 (en) * | 1999-05-13 | 2000-11-23 | Genzyme Transgenics Corp. | Transgenically produced antithrombin iii and mutants thereof |
DE19937656A1 (de) * | 1999-08-13 | 2001-02-15 | Aventis Behring Gmbh | Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8460367B2 (en) | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
EP1263484B1 (de) * | 2000-03-15 | 2007-05-16 | OrbusNeich Medical, Inc. | Beschichtung welche ein anhaften von endothelzellen stimuliert |
DE10102048A1 (de) * | 2001-01-17 | 2002-07-18 | Aventis Behring Gmbh | Antithrombin III gegen durch Angiogenese verursachte Krankheiten |
DE10159556A1 (de) * | 2001-12-05 | 2003-06-12 | Aventis Behring Gmbh Intellect | Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen |
DE10160133A1 (de) * | 2001-12-07 | 2003-06-26 | Transmit Technologietransfer | Verwendung von koagulationsaktivem Antithrombin III zur Therapie von Angiogenese-abhängigen Erkrankungen |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4087415A (en) | 1976-06-09 | 1978-05-02 | William L. Wilson | Antithrombin III |
US4517294A (en) | 1982-03-03 | 1985-05-14 | Genentech, Inc. | Human antithrombin III |
US4632981A (en) | 1982-07-30 | 1986-12-30 | Genentech, Inc. | Human antithrombin III |
DE3426903A1 (de) | 1984-07-20 | 1986-01-23 | Biotest Pharma GmbH, 6000 Frankfurt | Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten |
US5151509A (en) | 1988-12-16 | 1992-09-29 | United States Of America | Gene encoding serine protease inhibitor |
DE3901917A1 (de) | 1989-01-24 | 1990-07-26 | Behringwerke Ag | Mutanten von humanem antithrombin iii |
US5319072A (en) | 1992-01-10 | 1994-06-07 | Alpha Therapeutic Corporation | Human antithrombin-III preparation |
JP3479539B2 (ja) | 1992-04-10 | 2003-12-15 | エーザイ株式会社 | ヒトアンチトロンビンiii変異体 |
KR100330540B1 (ko) | 1993-04-05 | 2002-09-04 | 웰파이드 코포레이션 | 안티트롬빈-iii액상제제및그안정화방법 |
WO1999008522A1 (en) * | 1997-08-15 | 1999-02-25 | Ludwig Institute For Cancer Research | Stimulation, modulation and/or inhibition of endothelial proteolytic activity and/or angiogenic activity |
-
1999
- 1999-10-08 AT AT99954789T patent/ATE250427T1/de not_active IP Right Cessation
- 1999-10-08 US US09/414,834 patent/US6607724B2/en not_active Expired - Fee Related
- 1999-10-08 AU AU11051/00A patent/AU768076B2/en not_active Ceased
- 1999-10-08 CA CA002344613A patent/CA2344613A1/en not_active Abandoned
- 1999-10-08 WO PCT/US1999/023450 patent/WO2000020026A2/en active IP Right Grant
- 1999-10-08 EP EP99954789A patent/EP1117428B1/de not_active Expired - Lifetime
- 1999-10-08 DE DE69911629T patent/DE69911629D1/de not_active Expired - Lifetime
- 1999-10-08 JP JP2000573385A patent/JP2002526418A/ja active Pending
-
2003
- 2003-06-13 US US10/460,296 patent/US20030203838A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1117428A2 (de) | 2001-07-25 |
US20030203838A1 (en) | 2003-10-30 |
US20020076413A1 (en) | 2002-06-20 |
JP2002526418A (ja) | 2002-08-20 |
WO2000020026A2 (en) | 2000-04-13 |
DE69911629D1 (de) | 2003-10-30 |
AU768076B2 (en) | 2003-12-04 |
US6607724B2 (en) | 2003-08-19 |
CA2344613A1 (en) | 2000-04-13 |
AU1105100A (en) | 2000-04-26 |
WO2000020026A3 (en) | 2000-09-08 |
EP1117428B1 (de) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE230394T1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
ATE266675T1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
DK0950096T3 (da) | Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse | |
AU2002305450A1 (en) | Proteomimetic compounds and methods | |
ATE362766T1 (de) | Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen | |
DE60118003D1 (de) | Harnstoffderivate und ihre verwendung | |
BR9408025A (pt) | Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases | |
ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
MX9803851A (es) | Compuestos macrociclicos novedosos como inhibidores de metaloproteasas. | |
TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
ATE250427T1 (de) | Zusammensetzungen und deren verwendung zur hemmung von angiogenese | |
WO1999009000A3 (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
DK1206484T3 (da) | Antipicornavirale forbindelser og sammensætninger, deres farmaceutiske anvendelser og materialer til deres syntese | |
DE69735545D1 (de) | Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors | |
ATE299854T1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
ATE410155T1 (de) | Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung | |
DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
ATE230414T1 (de) | Mimetika von beta-faltblatt und verfahren zur verwendung davon | |
BRPI0416994A (pt) | inibidores de proteìna cinase com base em indolinona avançada | |
ATE393624T1 (de) | Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs | |
ES2117717T3 (es) | Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |